

1 WHAT IS CLAIMED IS:

- 2
- 3 1. A pharmaceutical composition comprising an effective amount of (R,R'),(R,S')-
4 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof,
5 substantially free of (S,R'),(S,S')-amphetaminil, and at least one
6 pharmaceutically-acceptable carrier, diluent, excipient or additive.
- 7
- 8 2. A controlled release formulation comprising the pharmaceutical composition of
9 claim 1.
- 10
- 11 3. An immediate release formulation comprising the pharmaceutical composition of
12 claim 1.
- 13
- 14 4. An oral dosage form comprising the pharmaceutical composition of claim 1
15 consisting of about 0.1 to about 100 mg of (R,R'),(R,S')-amphetaminil sulfate or
16 another pharmaceutically-acceptable salt thereof.
- 17
- 18 5. The dosage form of claim 4 consisting of about 1 to about 50 mg of (R,R'),(R,S')-
19 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof.
- 20
- 21 6. The pharmaceutical composition of claim 1 wherein said (R,R'),(R,S')-
22 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof is
23 greater than about 90% of the weight of total amphetaminil.

- 1
- 2 7. The pharmaceutical composition of claim 6 wherein said (R,R'),(R,S')-
- 3 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof is
- 4 greater than about 95% of the weight of total amphetaminil.
- 5
- 6 8. The pharmaceutical composition of claim 7 wherein said (R,R'),(R,S')-
- 7 amphetaminil sulfate or another pharmaceutically-acceptable salt thereof is
- 8 greater than about 99% of the weight of total amphetaminil.
- 9
- 10 9. A method for prophylaxis or treatment of a human condition or disease requiring
- 11 or benefitting from a central nervous stimulant comprising administering to said
- 12 human an effective amount of a pharmaceutical composition comprising
- 13 (R,R'),(R,S')-amphetaminil sulfate or another pharmaceutically-acceptable salt
- 14 thereof, substantially free of (S,R'),(S,S')-amphetaminil.
- 15
- 16 10. The method of claim 9 wherein said administering is parenteral, transmucosal or
- 17 transdermal.
- 18
- 19 11. The method of claim 10 wherein said transmucosal is orally, nasally, or rectally.
- 20
- 21 12. The method of claim 10 wherein said parenteral is intra-arterial, intravenous,
- 22 intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, or
- 23 intracranial.
- 24

1 13. The method of claim 9 wherein the amount administered is about 0.1 to about 100
2 mg daily.

3
4 14. The method of claim 13 wherein said amount administered is about 1 to about 50
5 mg daily.

6
7 15. The method of claim 14 wherein the amount is administered from one to about
8 four unit doses per day.

9
10 16. The method of claim 15 wherein the amount administered is one or two unit doses
11 per day.

12
13 17. The method of claim 5 wherein the amount of (R,R'),(R,S')-amphetaminil sulfate
14 or another pharmaceutically-acceptable salt thereof is greater than about 90% of
15 the weight of the total amphetaminil.

16
17 18. The method of claim 17 wherein the amount of (R,R'),(R,S')-amphetaminil
18 sulfate or another pharmaceutically-acceptable salt thereof is greater than about
19 95% of the weight of the total amphetaminil.

20
21 19. The method of claim 18 wherein the amount of (R,R'),(R,S')-amphetaminil
22 sulfate or another pharmaceutically-acceptable salt thereof is greater than about
23 99% of the weight of the total amphetaminil.

1
2 20. The method of claim 9 wherein said amount of (R,R'),(R,S')-amphetaminil
3 sulfate or another pharmaceutically-acceptable salt thereof, substantially free of
4 (S,R'),(S,S')-amphetaminil is administered together with a pharmaceutically-
5 acceptable carrier, diluent, excipient or additive.

6
7 21. The method of claim 9 wherein said condition or disease is narcolepsy, attention
8 deficit hyperactivity disorder (ADHD), depression, Parkinson's disease, cognitive
9 dysfunction, or Alzheimer's disease, renal dysfunction, asthma, obesity, nicotine
10 withdrawal, hypotension, apathy, potentiating activity of a conventional
11 antidepressant, potentiating an opiate for pain control, or reduced energy
12 associated with chemotherapy or radiation therapy.

13
14 22. The method of claim 9 wherein said condition or disease is amenable to treatment
15 by preferential activation of mesolimbic-mediated behavior.
16